Main > > >GASTROINTESTINAL STROMAL TUMORS. *

---

Treat.: Avapritinib Tablets.
[GIST>Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) Exon 18 Mutation
>METASTATIC Or UnResectable].
EU Approval Date: 2020. 09.25.
USA Approval Date: 2020. 01.09.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.26.




Treat.: Imatinib Mesylate Tablets.
KIT(CD117)+. Brand.
- after surgery who have had their KIT
(CD117)-positive GIST completely
removed
- cannot be surgically removed and/or
have spread to other parts of the body
(*) Company : Novartis.
Patent : Expired on 2015. 01.04.
TradeMark: Gleevec
Web-Site : www.us.gleevec.com
UpDate: 2018. 10.02.




Treat.: Imatinib Mesylate Tablets.
KIT(CD117)+. Generic.
- after surgery who have had their KIT
(CD117)-positive GIST completely
removed
- cannot be surgically removed and/or
have spread to other parts of the body
USA Launch Date: 2016. 08.05.
(*) Company : Apotex.
UpDate: 2018. 10.02.




Treat.: Imatinib Mesylate Tablets.
KIT(CD117)+. Generic.
- after surgery who have had their KIT
(CD117)-positive GIST completely
removed
- cannot be surgically removed and/or
have spread to other parts of the body
(*) Company : Cipla
TradeMark: Imatib
Web-Site :
ciplamed.com/content/imatib-tablets
UpDate: 2018. 10.02.




Treat.: Imatinib Mesylate Tablets.
KIT(CD117)+. Generic.
- after surgery who have had their KIT
(CD117)-positive GIST completely
removed
- cannot be surgically removed and/or
have spread to other parts of the body
USA Launch Date: 2018. 10.01.
(*) Company : Dr. Reddy s Laboratories
UpDate: 2018. 10.02.




Treat.: Imatinib Mesylate Tablets.
KIT(CD117)+. Generic.
- after surgery who have had their KIT
(CD117)-positive GIST completely
removed
- cannot be surgically removed and/or
have spread to other parts of the body
USA Approval Date: 2016. 02.01.
(*) Company : Sun Pharma
UpDate: 2018. 10.02.




Treat.: Imatinib Mesylate Tablets.
KIT(CD117)+. Generic.
- after surgery who have had their KIT
(CD117)-positive GIST completely
removed
- cannot be surgically removed and/or
have spread to other parts of the body
USA Launch Date: 2016. 08.05.
(*) Company : Teva Pharma.
UpDate: 2018. 10.02.




Treat.: Regorafenib.
Oral Multi Kinase Inhibition.
CN, EU & JP Approval Date: ?
USA Approval Date : 2012. 09.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.02.




Treat.: Ripretinib Tablets>
>3 Prior Treat. Kinase Inhibitors.
AU Approval Date: 2020. 07.14.
CA Approval Date: 2020. 06.22.
USA Launch Date: 2020. 06.04.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.21.




Treat.: Sunitinib Malate.
JP Approval Date : ?
USA Approval Date: 2006. 01.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.02.



>GASTROINTESTINAL STROMAL TUMORS. *'s products
This section has no products